Loading, Please Wait...
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, today announced that Leslie Williams, Chief Executive Officer, will present a corporate overview at the Cowen & Company 39th Annual Healthcare Conference, taking place March 11-13 in Boston, Massachusetts.
Cowen 39th Annual Health Care Conference
|Date:||Monday, March 11|
|Time:||3:00pm Eastern Time|
About ImmusanT, Inc.
At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com
LifeSci Public Relations